MedTrace Logo

Effect of Xolair on Airway Hyperresponsiveness

NCT00208234 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2011-09-23

No results posted yet for this study

Summary

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Conditions

  • Allergic Asthma

Interventions

DRUG

Omalizumab

0.016 mg/kg IgE

DRUG

Placebo for Omalizumab

Placebo

DRUG

omalizumab

Monoclonal antibody against IgE. 0.016 mg/kg IgE

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Thomas B Casale, MD · Creighton University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208234 on ClinicalTrials.gov